Linda D. Bosserman, MD, of City of Hope, discusses guidelines vs pathways, how to personalize pathways, integrated diagnostics, supportive care regimens, and financial guidance for patients with cancer.
Bernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive non–small cell lung cancer (Abstract 3).
Manali I. Patel, MD, of Stanford Cancer Center, discusses enhancing value for patients with cancer treated by community practitioners at the end of life by also utilizing trained lay health workers in a novel intervention that reduced the use of acute care and emergency department visits while improving quality of life.
Michael Kenneth Keng, MD, of the University of Virginia, gives a status update on this international program, and discusses future initiatives which include coaching mentorship and publishing articles on quality care (Abstract 7).
Cary P. Gross, MD, of Yale School of Medicine, discusses the challenges of implementing pathways and guiding patient decision-making on treatment.
Karen M. Winkfield, MD, PhD, of the Wake Forest Baptist Medical Center, discusses cultural factors that contribute to cancer care disparities, the role of national policy in addressing inequities in access to care, and what local institutions can do to improve the situation.
